Technical Analysis for TPST - Tempest Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bollinger Band Squeeze | Range Contraction | 0.94% | |
| Stochastic Reached Oversold | Weakness | 0.94% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.94% | |
| Down 3 Days in a Row | Weakness | 0.94% | |
| Lower Bollinger Band Touch | Weakness | 0.94% | |
| Oversold Stochastic | Weakness | 0.94% | |
| Bollinger Band Squeeze | Range Contraction | -0.31% | |
| BB Squeeze Started | Range Contraction | -0.31% | |
| 20 DMA Resistance | Bearish | -5.03% | |
| Shooting Star Candlestick | Bearish | -5.03% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 1 hour ago |
| Up 3% | about 1 hour ago |
| 60 Minute Opening Range Breakout | about 1 hour ago |
| Up 2% | about 2 hours ago |
| Up 1% | about 3 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 06/13/2024
Tempest Therapeutics, Inc. Description
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecules that combine targeted and immune-mediated mechanisms with the potential to treat various tumors. The company's two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARa. Its TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study agents as monotherapies and in combination with other approved agents. The company is also developing an orally-available inhibitor of TREX-1 designed to activate selectively the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. The company is headquartered in South San Francisco, California. Tempest Therapeutics Inc. operates as a subsidiary of Inception Sciences, Inc.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Tumor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.0 |
| 52 Week Low | 0.17 |
| Average Volume | 962,273 |
| 200-Day Moving Average | 3.07 |
| 50-Day Moving Average | 3.64 |
| 20-Day Moving Average | 3.44 |
| 10-Day Moving Average | 3.40 |
| Average True Range | 0.25 |
| RSI (14) | 39.76 |
| ADX | 11.73 |
| +DI | 18.97 |
| -DI | 24.15 |
| Chandelier Exit (Long, 3 ATRs) | 3.04 |
| Chandelier Exit (Short, 3 ATRs) | 3.81 |
| Upper Bollinger Bands | 3.75 |
| Lower Bollinger Band | 3.14 |
| Percent B (%b) | 0.06 |
| BandWidth | 17.59 |
| MACD Line | -0.10 |
| MACD Signal Line | -0.08 |
| MACD Histogram | -0.0202 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.39 | ||||
| Resistance 3 (R3) | 3.39 | 3.33 | 3.36 | ||
| Resistance 2 (R2) | 3.33 | 3.27 | 3.33 | 3.34 | |
| Resistance 1 (R1) | 3.25 | 3.24 | 3.22 | 3.25 | 3.33 |
| Pivot Point | 3.19 | 3.19 | 3.17 | 3.19 | 3.19 |
| Support 1 (S1) | 3.11 | 3.13 | 3.08 | 3.11 | 3.03 |
| Support 2 (S2) | 3.05 | 3.10 | 3.05 | 3.02 | |
| Support 3 (S3) | 2.97 | 3.05 | 3.01 | ||
| Support 4 (S4) | 2.97 |
